70
Management
4.2.8.2. Young Adults >18 to 39 Years of Age
COR LOE
Recommendation
1 B-NR
1. In young adults (>18 to 39 years of age), dietary, physical
activity, and weight optimization recommendations should
be provided to reduce cumulative atherogenic lipid exposure
and lifetime ASCVD risk.
4.2.8.3. Older Adults
COR LOE
Recommendations
1 C-EO
1. In older adults, the benefit-risk discussion should include
patient priorities, functional status, multimorbidity, frailty,
polypharmacy, and life expectancy, and should not be based
solely on chronological age when considering the decision to
discontinue LLT.
2b B-NR
2. In adults aged >75 years with an estimated life expectancy of
at least 2.5 years, it may be reasonable to initiate moderate-
intensity statin therapy after a clinician-patient discussion of
potential benefits and risks to reduce ASCVD risk.
2b B-R
3. In patients with a life expectancy of <1 year, it may be
reasonable to discontinue LDL-lowering therapy to avoid
unnecessary medication use or adverse medication effects.
2b B-NR
4. In adults aged >75 years with an estimated life expectancy of
at least 2.5 years, and for whom the decision regarding LLT is
uncertain, it may be reasonable to measure CAC to reclassify
those with minimal (1-10) or no CAC to avoid LLT.
